Insights

Innovative Oncology Platform OncoTEX has developed TEX Core, a groundbreaking platform aimed at overcoming resistance in oncology therapies, positioning the company as a key innovator in the cancer treatment market.

Pipeline Development With OxaliTEX as its first clinical candidate targeting platinum-resistant ovarian cancer, OncoTEX offers opportunities to collaborate with pharmaceutical companies interested in expanding their oncology portfolios.

Strategic Leadership The recent appointment of Dr. Jonathan F. Arambula as CEO indicates a focus on strategic growth and investor confidence, which could accelerate partnership prospects and funding opportunities.

Funding & Growth Potential While specific funding data is unavailable, OncoTEX operates within a competitive biotech space with revenue estimates between one and ten million dollars, signaling room for growth and potential market capture.

Market Positioning Positioned alongside other prominent research institutions and cancer centers, OncoTEX's innovative therapies present opportunities to engage with clinical trial partnerships and early adoption programs.

Similar companies to OncoTEX

OncoTEX Tech Stack

OncoTEX uses 8 technology products and services including MySQL, Google Fonts API, Next.js, and more. Explore OncoTEX's tech stack below.

MySQL
Database
Google Fonts API
Font Scripts
Next.js
Javascript Frameworks
Mapbox.js
Maps
HSTS
Security
Google Tag Manager
Tag Management
X-Content-Type-Options
Web & Portal Technology
Nginx
Web Servers

Media & News

OncoTEX Inc. hires Jonathan F. Arambula as Chief Executive Officer.
OncoTEX Inc. (OncoTEX), a US oncology company and member of The iQ Group Global Ltd portfolio (NSX.IQG), is pleased to announce it has appointed Dr. Jonathan F. Arambula as Chief Executive Officer.
Oct 25, 2021 | theiqgroupglobal.com

OncoTEX's Email Address Formats

OncoTEX uses at least 2 format(s):

OncoTEX Email Formats	Example	Percentage
First@columbusccop.org	John@columbusccop.org	54%
FirstL@columbusccop.org	JohnD@columbusccop.org	38%
FLast@columbusccop.org	JDoe@columbusccop.org	8%

Frequently Asked Questions

What is OncoTEX's phone number?

You can contact OncoTEX's main corporate office by phone at

+1-614-488-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is OncoTEX's official website and social media links?

OncoTEX's official website is oncotexinc.com and has social profiles on LinkedIn.

What is OncoTEX's SIC code NAICS code?

OncoTEX's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does OncoTEX have currently?

As of December 2025, OncoTEX has approximately 51 employees across 1 continents, including North America. Key team members include Executive Director - Columbus Ncorp: J. H.Compliance Manager: A. P.Principal Investigator: T. M.. Explore OncoTEX's employee directory with LeadIQ.

What industry does OncoTEX belong to?

OncoTEX operates in the Biotechnology Research industry.

What technology does OncoTEX use?

OncoTEX's tech stack includes MySQLGoogle Fonts APINext.jsMapbox.jsHSTSGoogle Tag ManagerX-Content-Type-OptionsNginx.

What is OncoTEX's email format?

OncoTEX's email format typically follows the pattern of First@columbusccop.org. Find more OncoTEX email formats with LeadIQ.

OncoTEX

Q: What is OncoTEX's official website and social media links?

OncoTEX's official website is oncotexinc.com. OncoTEX has social profiles on LinkedIn.

Q: How many employees does OncoTEX have currently?

OncoTEX has approximately 51 employees.

Q: What technology does OncoTEX use?

OncoTEX's tech stack includes PHP, Cloudflare CDN, Google Fonts API, jQuery, HSTS.

Biotechnology ResearchTexas, United States51-200 Employees

OncoTEX is developing TEX Core, a world-first oncology drug platform designed to create innovative therapies capable of overcoming multiple limitations often associated with current cancer therapeutics, including the predominant platinum-based resistance. OxaliTEX is the first clinical candidate developed from the TEX Core platform for the treatment of platinum-resistant ovarian cancer. TEX Core is designed to target tumor cells by overcoming challenges associated with the current platinum-based standards-of-care (SOC).

Company Overview

Phone number: +1-614-488-****
Website: oncotexinc.com
SIC Code: 8733 - Noncommercial Research Organizations
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 51-200